Regulation of Drug Marketing: An Introduction
Learn to differentiate between “label” and “labeling” and “false and “misleading”. Gain insight on FDA’s social media guidance, use of off-label information, and considerations for other government and state entities. Understand the role of a corporate compliance program in managing the risks of marketing a drug.
Laura S. Dona, Associate, Arnall Golden Gregory LLP
Alan G. Minsk, Partner and Co-Chair of Food and Drug Practice Team, Arnall Golden Gregory LLP
This session was recorded as part of FDLI’s Introduction to Drug Law and Regulation Course in November 2023.
Get Access
- +$100 for nonmembers
Internet Explorer and Microsoft Edge are not supported by the checkout process.
Please use Chrome, Firefox, or Safari. If you are unable to use these browsers, please contact us at 202-371-1420 or [email protected] and we will assist you.
Virtual Learning FAQ
Related Content